GCP
MLTX icon

GSA Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

GSA Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Buy
106,695
+26,462
+33% +$480K 0.13% 150
2026
Q1 		$1.5M Sell
80,233
-9,003
-10% -$149K 0.09% 284
2025
Q4 		$1.18M Buy
+89,236
New +$1.05M 0.1% 272
2024
Q4 		– Sell
-22,127
Closed -$1.12M – 1860
2024
Q3 		$1.12M Buy
22,127
+403
+2% +$18.9K 0.08% 406
2024
Q2 		$955K Buy
+21,724
New +$920K 0.07% 534

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's MLTX Position: Q2 2026 in Review

GSA Capital Partners increased its MoonLake Immunotherapeutics (MLTX) stake by 33% in Q2 2026, buying an estimated $480K and bringing the position to 106,695 shares worth $2.08M. The position accounts for 0.13% of the portfolio, ranked #150.

GSA Capital Partners first reported a position in MLTX in Q2 2024 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • GSA Capital Partners held 106,695 shares of MoonLake Immunotherapeutics worth $2.08M as of Q2 2026.
  • GSA Capital Partners bought 26,462 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $480K.
  • MoonLake Immunotherapeutics made up 0.13% of GSA Capital Partners's portfolio in Q2 2026, its #150 holding.
  • GSA Capital Partners first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.